DISCUSSION
autism spectrum disorder, schizophrenia, illness
ADVERSE EVENTS
L‐Carnosine is widely used as an antioxidant and neutraceutical agent. Studies in L‐carnosine had used variable dosing of 200 mg–2 g across schizophrenia and autism spectrum disorder. A recent study from Tehran proposed that this drug improves negative symptoms and cognition and highlighted that a 2 g dose of L‐Carnosine is necessary to exert any glutamatergic or NMDA modulatory effects in schizophrenia.In summary, controlling for combined effects of confounding variables such as age and gender, matching illness severity (SANS score > 60) in the two groups, concurrent antipsychotic medications, chronic nature of the illness, and placebo response were insufficient to produce the desired results.A larger multicenter longitudinal study using higher doses of L‐carnosine 2 g or more should be planned to explore the desired efficacy of the drug in improving all domains of cognition and negative symptoms.This current study and all previous studies using L‐Carnosine in schizophrenia did not report any major adverse events.